Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: Their potential application to gastrointestinal cancers

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 4, 2011, Pages 729-739

  Shimoyama, Shouji ^a  

^a Settlement Clinic   (Japan)

Author keywords

Colorectal cancer; Gastric cancer; K Ras oncogene; Molecular targeting therapy; Statins

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ATORVASTATIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; K RAS PROTEIN; MEVALONIC ACID; MEVINOLIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SORAFENIB; TRASTUZUMAB; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CELL AGING; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TARGETING; ENZYME SUBSTRATE; ESOPHAGUS CANCER; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYPERLIPIDEMIA; INHIBITION KINETICS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL LITERATURE; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRENYLATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GENES, RAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RATS; SURVIVAL;

EID: 79954437299     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-011-1583-2     Document Type: Review

References (105)

1. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka H Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 18282805 10.1016/S1470-2045(08)70035-4 1:CAS:528: DC%2BD1cXivVaqtb4%3D
2. B Glimelius K Hoffman U Haglund O Nyrén PO Sjödén 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190 8186165 1:STN:280:DyaK2c3kt1KrsA%3D%3D (Pubitemid 24062577)
3. RM Goldberg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pitot SR Alberts 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 14665611 10.1200/JCO.2004.09.046 1:CAS:528:DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
4. CS Fuchs J Marshall E Mitchell R Wierzbicki V Ganju M Jeffery J Schulz D Richards R Soufi-Mahjoubi B Wang J Barrueco 2007 Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 4779 4786 17947725 10.1200/JCO.2007.11.3357 1:CAS:528: DC%2BD2sXhtlCgsLbM (Pubitemid 350086481)
5. H Narahara K Fujitani H Takiuchi N Sugimoto K Inoue N Uedo H Tsukuma T Tsujinaka H Furukawa T Taguchi 2008 Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer Oncology 74 37 41 18544958 10.1159/000138978 1:CAS:528:DC%2BD1cXnvFSjs70%3D (Pubitemid 351915008)
6. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
7. S Siena A Sartore-Bianchi F Di Nicolantonio J Balfour A Bardelli 2009 Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 1308 1324 19738166 10.1093/jnci/djp280 1:CAS:528:DC%2BD1MXht1Ojt73I
8. KK Chan AM Oza LL Siu 2003 The statins as anticancer agents Clin Cancer Res 9 10 19 12538446 1:CAS:528:DC%2BD3sXnt1OnsQ%3D%3D (Pubitemid 36109711)
9. F Ciardiello G Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 1160 1174 18337605 10.1056/NEJMra0707704 1:CAS:528:DC%2BD1cXjt1ahsL4%3D (Pubitemid 351398490)
10. MR Graaf DJ Richel CJ van Noorden HJ Guchelaar 2004 Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer Cancer Treat Rev 30 609 641 15531395 10.1016/j.ctrv.2004.06.010 1:CAS:528:DC%2BD2cXpsVOltb0%3D (Pubitemid 39451828)
11. AJ Ridley 2001 Rho family proteins: coordinating cell responses Trends Cell Biol 11 471 477 11719051 10.1016/S0962-8924(01)02153-5 1:CAS:528: DC%2BD3MXosFKls78%3D (Pubitemid 33079138)
12. P Rodriguez-Viciana PH Warne R Dhand B Vanhaesebroeck I Gout MJ Fry MD Waterfield J Downward 1994 Phosphatidylinositol-3-OH kinase as a direct target of Ras Nature 370 527 532 8052307 10.1038/370527a0 1:CAS:528:DyaK2cXmsV2hs7w%3D (Pubitemid 24264918)
13. K Pruitt CJ Der 2001 Ras and Rho regulation of the cell cycle and oncogenesis Cancer Lett 171 1 10 11485822 10.1016/S0304-3835(01)00528-6 1:CAS:528:DC%2BD3MXls1ejt7g%3D (Pubitemid 32727350)
14. Gingras D, Lamy S, Béliveau R (2000) Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J 348(Pt 2):273-280 (Pubitemid 30345198)
15. BA Bryan PA D'Amore 2007 What tangled webs they weave: Rho-GTPase control of angiogenesis Cell Mol Life Sci 64 2053 2065 17530172 10.1007/s00018-007- 7008-z 1:CAS:528:DC%2BD2sXhtVaisb7J (Pubitemid 350092415)
16. GP van Nieuw Amerongen P Koolwijk A Versteilen VW van Hinsbergh 2003 Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro Arterioscler Thromb Vasc Biol 23 211 217 12588761 10.1161/01.ATV.0000054198.68894.88 (Pubitemid 36231930)
17. M Guba H Seeliger A Kleespies KW Jauch C Bruns 2004 Vascular endothelial growth factor in colorectal cancer Int J Colorectal Dis 19 510 517 14999511 10.1007/s00384-003-0576-y (Pubitemid 39445405)
18. J Iwasaki S Nihira 2009 Anti-angiogenic therapy against gastrointestinal tract cancers Jpn J Clin Oncol 39 543 551 19531544 10.1093/jjco/hyp062
19. T Ichikura S Tomimatsu E Ohkura H Mochizuki 2001 Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma J Surg Oncol 78 132 137 11579392 10.1002/jso.1133 1:CAS:528:DC%2BD3MXnslKhur8%3D (Pubitemid 32906126)
20. O Vidal JP Metges I Elizalde M Valentíni A Volant R Molina A Castells M Pera 2009 High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer Br J Surg 96 1443 1451 19918848 10.1002/bjs.6780 1:CAS:528: DC%2BC3cXjslOgtg%3D%3D
21. Y Takahashi Y Kitadai CD Bucana KR Cleary LM Ellis 1995 Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer Cancer Res 55 3964 3968 7664263 1:CAS:528:DyaK2MXotV2msLg%3D
22. JT Jørgensen 2010 Targeted HER2 treatment in advanced gastric cancer Oncology 78 26 33 20185938 10.1159/000288295
23. YJ Bang E Van Cutsem A Feyereislova HC Chung L Shen A Sawaki F Lordick A Ohtsu Y Omuro T Satoh G Aprile E Kulikov J Hill M Lehle J Rüschoff YK Kang ToGA Trial Investigators 2010 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687 697 20728210 10.1016/S0140-6736(10)61121-X 1:CAS:528:DC%2BC3cXhtVymt7zO
24. http://www.ClinicalTrial.gov. Accessed Aug 2010
25. Kang Y, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park S, Lim H, Wu J, Langer B, Shah MA (2010) AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). Proc ASCO abstr LBA 4007
26. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 15269313 10.1056/NEJMoa033025 1:CAS:528: DC%2BD2cXlvFGitbk%3D (Pubitemid 38944402)
27. AF Sobrero J Maurel L Fehrenbacher W Scheithauer YA Abubakr MP Lutz ME Vega-Villegas C Eng EU Steinhauer J Prausova HJ Lenz C Borg G Middleton H Kröning G Luppi O Kisker A Zubel C Langer J Kopit HA Burris 3rd 2008 EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2311 2319 18390971 10.1200/JCO.2007.13.1193 1:CAS:528:DC%2BD1cXntVOltrk%3D
28. DJ Jonker CJ O'Callaghan CS Karapetis JR Zalcberg D Tu HJ Au SR Berry M Krahn T Price RJ Simes NC Tebbutt G van Hazel R Wierzbicki C Langer MJ Moore 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040 2048 18003960 10.1056/NEJMoa071834 1:CAS:528:DC%2BD2sXhtlWis7rI (Pubitemid 350106711)
29. E Van Cutsem CH Köhne E Hitre J Zaluski CR Chang Chien A Makhson G D'Haens T Pintér R Lim G Bodoky JK Roh G Folprecht P Ruff C Stroh S Tejpar M Schlichting J Nippgen P Rougier 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 19339720 10.1056/NEJMoa0805019
30. C Bokemeyer I Bondarenko A Makhson JT Hartmann J Aparicio F de Braud S Donea H Ludwig G Schuch C Stroh AH Loos A Zubel P Koralewski 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 19114683 10.1200/JCO.2008.20.8397 1:CAS:528:DC%2BD1MXjsVCjsrk%3D
31. E Van Cutsem M Peeters S Siena Y Humblet A Hendlisz B Neyns JL Canon JL Van Laethem J Maurel G Richardson M Wolf RG Amado 2007 Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 1658 1664 17470858 10.1200/JCO.2006.08.1620 (Pubitemid 46797944)
32. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 14993230 10.1200/JCO.2004.10.182 1:CAS:528:DC%2BD2cXpsVGktLw%3D (Pubitemid 41079832)
33. KY Chung J Shia NE Kemeny M Shah GK Schwartz A Tse A Hamilton D Pan D Schrag L Schwartz DS Klimstra D Fridman DP Kelsen LB Saltz 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810 15677699 10.1200/JCO.2005.08.037 1:CAS:528:DC%2BD2MXjt1Ckuro%3D (Pubitemid 46211358)
34. F Di Nicolantonio M Martini F Molinari A Sartore-Bianchi S Arena P Saletti S De Dosso L Mazzucchelli M Frattini S Siena A Bardelli 2008 Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705 5712 19001320 10.1200/JCO.2008.18.0786 1:CAS:528:DC%2BD1MXotFemsA%3D%3D
35. CJ Allegra JM Jessup MR Somerfield SR Hamilton EH Hammond DF Hayes PK McAllister RF Morton RL Schilsky 2009 American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091 2096 19188670 10.1200/JCO.2009.21.9170
36. Y Jiang ET Kimchi KF Staveley-O'Carroll H Cheng JA Ajani 2009 Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer Cancer 115 3609 3617 19526592 10.1002/cncr.24434 1:CAS:528:DC%2BD1MXhtVOnurjF
37. RG Amado M Wolf M Peeters E Van Cutsem S Siena DJ Freeman T Juan R Sikorski S Suggs R Radinsky SD Patterson DD Chang 2008 Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 18316791 10.1200/JCO.2007.14.7116 1:CAS:528: DC%2BD1cXltlWhsrw%3D
38. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954 (Pubitemid 34716871)
39. C Riganti E Aldieri S Doublier A Bosia D Ghigo 2008 Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy Mini Rev Med Chem 8 609 618 18537716 10.2174/138955708784534436 1:CAS:528: DC%2BD1cXmslOhsro%3D
40. D Stokoe SG Macdonald K Cadwallader M Symons JF Hancock 1994 Activation of Raf as a result of recruitment to the plasma membrane Science 264 1463 1467 7811320 10.1126/science.7811320 1:CAS:528:DyaK2cXksFClsr0%3D (Pubitemid 24217138)
41. SJ Leevers HF Paterson CJ Marshall 1994 Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane Nature 369 411 414 8196769 10.1038/369411a0 1:CAS:528:DyaK2cXlsFWqtro%3D (Pubitemid 24184056)
42. PJ Casey 1995 Protein lipidation in cell signaling Science 268 221 225 7716512 10.1126/science.7716512 1:CAS:528:DyaK2MXltVCitLs%3D
43. EK Rowinsky JJ Windle DD Von Hoff 1999 Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development J Clin Oncol 17 3631 3652 10550163 1:CAS:528:DyaK1MXnvVGltLc%3D (Pubitemid 29517936)
44. L Sepp-Lorenzino Z Ma E Rands NE Kohl JB Gibbs A Oliff N Rosen 1995 A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines Cancer Res 55 5302 5309 7585592 1:CAS:528:DyaK2MXpsVaqsr0%3D
45. Kawata M, Farnsworth CC, Yoshida Y, Gelb MH, Glomset JA, Takai Y (1990) Posttranslationally processed structure of the human platelet protein smg p21B: evidence for geranylgeranylation and carboxyl methylation of the C-terminal cysteine. Proc Natl Acad Sci USA 87:8960-8964 (Pubitemid 120007629)
46. Cox AD, Hisaka MM, Buss JE, Der CJ (1992) Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol 12:2606-2615
47. Y Yoshida M Kawata M Katayama H Horiuchi Y Kita Y Takai 1991 A geranylgeranyltransferase for rhoA p21 distinct from the farnesyltransferase for ras p21S Biochem Biophys Res Commun 175 720 728 1902099 10.1016/0006-291X(91) 91625-M 1:CAS:528:DyaK3MXkvVOqsro%3D
48. CA Rowell JJ Kowalczyk MD Lewis AM Garcia 1997 Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo J Biol Chem 272 14093 14097 9162034 10.1074/jbc.272.22.14093 1:CAS:528:DyaK2sXjsFOjtro%3D (Pubitemid 27232813)
49. L Vincent W Chen L Hong F Mirshahi Z Mishal T Mirshahi-Khorassani JP Vannier J Soria C Soria 2001 Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect FEBS Lett 495 159 166 11334884 10.1016/S0014-5793(01) 02337-7 1:CAS:528:DC%2BD3MXjtFGht7w%3D (Pubitemid 32397697)
50. JL Bos 1989 Ras oncogenes in human cancer: a review Cancer Res 49 4682 4689 2547513 1:CAS:528:DyaL1MXltlWksL4%3D (Pubitemid 19213607)
51. HJ Andreyev AR Norman D Cunningham JR Oates PA Clarke 1998 Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 675 684 9586664 10.1093/jnci/90.9.675 1:CAS:528:DyaK1cXjtlSiu7s%3D (Pubitemid 28222141)
52. G Fritz I Just B Kaina 1999 Rho GTPases are over-expressed in human tumors Int J Cancer 81 682 687 10328216 10.1002/(SICI)1097-0215(19990531)81: 5<682::AID-IJC2>3.0.CO;2-B 1:CAS:528:DyaK1MXjtF2kt7o%3D (Pubitemid 29214373)
53. N Liu G Zhang F Bi Y Pan Y Xue Y Shi L Yao L Zhao Y Zheng D Fan 2007 RhoC is essential for the metastasis of gastric cancer J Mol Med 85 1149 1156 17549441 10.1007/s00109-007-0217-y 1:CAS:528:DC%2BD2sXhtVOit7%2FL (Pubitemid 47476732)
54. N Liu F Bi Y Pan L Sun Y Xue Y Shi X Yao Y Zheng D Fan 2004 Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity Clin Cancer Res 10 6239 6247 15448013 10.1158/1078-0432.CCR-04- 0242 1:CAS:528:DC%2BD2cXnvVOjsLs%3D (Pubitemid 39287532)
55. EC Lerner Y Qian MA Blaskovich RD Fossum A Vogt J Sun AD Cox CJ Der AD Hamilton SM Sebti 1995 Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes J Biol Chem 270 26802 26806 7592920 10.1074/jbc.270.45.26802 1:CAS:528:DyaK2MXpsVGlsr8%3D (Pubitemid 3007240)
56. DB Whyte P Kirschmeier TN Hockenberry I Nunez-Oliva L James JJ Catino WR Bishop JK Pai 1997 K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272 14459 14464 9162087 10.1074/jbc.272.22.14459 1:CAS:528:DyaK2sXjsFygs74%3D (Pubitemid 27232866)
57. S Rao D Cunningham A de Gramont W Scheithauer M Smakal Y Humblet G Kourteva T Iveson T Andre J Dostalova A Illes R Belly JJ Perez-Ruixo YC Park PA Palmer 2004 Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer J Clin Oncol 22 3950 3957 15459217 10.1200/JCO.2004.10.037 1:CAS:528:DC%2BD2cXpsVKitrk%3D (Pubitemid 41079877)
58. A Vogt J Sun Y Qian AD Hamilton SM Sebti 1997 The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner J Biol Chem 272 27224 27229 9341167 10.1074/jbc.272.43.27224 1:CAS:528:DyaK2sXmvFyrt7Y%3D (Pubitemid 27452683)
59. J Sun MA Blaskovich D Knowles Y Qian J Ohkanda RD Bailey AD Hamilton SM Sebti 1999 Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine Cancer Res 59 4919 4926 10519405 1:CAS:528:DyaK1MXmslWktLc%3D (Pubitemid 29472897)
60. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, de Solms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE (2001) Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 61:8758-8768 (Pubitemid 34013888)
61. JL Goldstein MS Brown 1990 Regulation of the mevalonate pathway Nature 343 425 430 1967820 10.1038/343425a0 1:CAS:528:DyaK3cXhtlCmtbw%3D (Pubitemid 20065229)
62. V Kaushal M Kohli P Mehta JL Mehta 2003 Potential anticancer effects of statins: fact or fiction? Endothelium 10 49 58 12699077 10.1080/10623320303358 1:CAS:528:DC%2BD3sXitVCnu7o%3D (Pubitemid 36355983)
63. IK Wang SY Lin-Shiau JK Lin 2000 Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation Oncology 59 245 254 11053993 10.1159/000012168 1:CAS:528:DC%2BD3cXnvVOjtL8%3D
64. J Lee I Lee C Park WK Kang 2006 Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Biochem Biophys Res Commun 339 748 754 16316623 10.1016/j.bbrc.2005.11.075 1:CAS:528:DC%2BD2MXhtlajtLvK (Pubitemid 41772877)
65. EA Collisson C Kleer M Wu A De SS Gambhir SD Merajver MS Kolodney 2003 Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells Mol Cancer Ther 2 941 948 14578459 1:CAS:528:DC%2BD3sXosVCqt74%3D
66. HJ Park D Kong L Iruela-Arispe U Begley D Tang JB Galper 2002 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA Circ Res 91 143 150 12142347 10.1161/01.RES.0000028149.15986.4C 1:CAS:528:DC%2BD38XlvVCgsL8%3D (Pubitemid 34827225)
67. T Kusama M Mukai T Iwasaki M Tatsuta Y Matsumoto H Akedo H Nakamura 2001 Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors Cancer Res 61 4885 4891 11406567 1:CAS:528: DC%2BD3MXks1Gru7s%3D (Pubitemid 32691906)
68. TT Zhao BG Le Francois G Goss K Ding PA Bradbury J Dimitroulakos 2010 Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins Oncogene 29 4682 4692 20562912 10.1038/onc.2010.219 1:CAS:528:DC%2BC3cXns1Gjt7o%3D
69. S Kato S Smalley A Sadarangani K Chen-Lin B Oliva J Brañes J Carvajal R Gejman GI Owen M Cuello 2010 Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase J Cell Mol Med 14 1180 1193 19432822 1:CAS:528: DC%2BC3cXpslOlu7c%3D
70. G Bocci A Fioravanti P Orlandi N Bernardini P Collecchi M Del Tacca R Danesi 2005 Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells Br J Cancer 93 319 330 16052215 10.1038/sj.bjc.6602720 1:CAS:528:DC%2BD2MXmvFensb0%3D (Pubitemid 43080034)
71. M Asakage NH Tsuno J Kitayama K Kawai Y Okaji K Yazawa S Kaisaki K Takahashi H Nagawa 2004 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest Anticancer Drugs 15 625 632 15205608 10.1097/01.cad. 0000131680.83518.91 1:CAS:528:DC%2BD2cXkvV2ntbs%3D (Pubitemid 38932333)
72. RJ Macaulay W Wang J Dimitroulakos LE Becker H Yeger 1999 Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro J Neurooncol 42 1 11 10360474 10.1023/A:1006164406202 1:STN:280: DyaK1M3oslaiuw%3D%3D (Pubitemid 29216785)
73. OO Ogunwobi IL Beales 2008 Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells Am J Gastroenterol 103 825 837 18371146 10.1111/j.1572-0241.2007.01773.x 1:CAS:528:DC%2BD1cXls1CqsL0%3D (Pubitemid 351501115)
74. XQ Xu TF McGuire MA Blaskovich SM Sebti G Romero 1996 Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts Arch Biochem Biophys 326 233 237 8611028 10.1006/abbi.1996.0070 1:CAS:528:DyaK28XhtFajsb8%3D (Pubitemid 26060138)
75. MD Johnson A Woodard EJ Okediji SA Toms GS Allen 2002 Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase J Neurooncol 56 133 142 11995814 10.1023/A:1014588214966 (Pubitemid 34272304)
76. M Takata M Urakaze R Temaru K Yamazaki N Nakamura Y Nobata M Kishida A Sato M Kobayashi 2001 Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase Br J Pharmacol 134 753 762 11606315 10.1038/sj.bjp.0704305 1:CAS:528:DC%2BD3MXotlChsLk%3D (Pubitemid 33016146)
77. E Roudier O Mistafa U Stenius 2006 Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs Mol Cancer Ther 5 2706 2715 17121917 10.1158/1535-7163.MCT-06-0352 1:CAS:528:DC%2BD28Xht1els7nK (Pubitemid 44848997)
78. AP Sutter K Maaser M Höpfner A Huether D Schuppan H Scherübl 2005 Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor J Hepatol 43 808 816 16083991 10.1016/j.jhep.2005.04.010 1:CAS:528:DC%2BD2MXhtVyntr3P (Pubitemid 41414506)
79. DZ Hillyard AJ Cameron AH McIntyre MH Hadden HE Marshall N Johnston AG Jardine 2002 Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin Clin Exp Pharmacol Physiol 29 673 678 12099998 10.1046/j.1440-1681.2002.03711.x 1:CAS:528:DC%2BD38XlsV2htro%3D (Pubitemid 34779617)
80. S Nishida H Matsuoka M Tsubaki Y Tanimori M Yanae Y Fujii M Iwaki 2005 Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK Mol Cell Biochem 269 109 114 15786722 10.1007/s11010-005- 3086-0 1:CAS:528:DC%2BD2MXhtl2kt7k%3D (Pubitemid 40287807)
81. Y Sekine Y Furuya M Nishii H Koike H Matsui K Suzuki 2008 Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor Biochem Biophys Res Commun 372 356 361 18489904 10.1016/j.bbrc.2008.05.043 1:CAS:528: DC%2BD1cXmvFentbw%3D
82. N Ghosh-Choudhury CC Mandal N Ghosh-Choudhury G Ghosh Choudhury 2010 Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth Cell Signal 22 749 758 20060890 10.1016/j.cellsig. 2009.12.010 1:CAS:528:DC%2BC3cXit1WqtLg%3D
83. I Takeda S Maruya T Shirasaki H Mizukami T Takahata JN Myers S Kakehata S Yagihashi H Shinkawa 2007 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells Cancer Sci 98 890 899 17428261 10.1111/j.1349-7006.2007.00471.x 1:CAS:528:DC%2BD2sXmsVWmtLw%3D (Pubitemid 46691828)
84. B Agarwal S Bhendwal B Halmos SF Moss WG Ramey PR Holt 1999 Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells Clin Cancer Res 5 2223 2229 10473109 1:CAS:528:DyaK1MXlvVOhu70%3D (Pubitemid 29399281)
85. J Dimitroulakos LY Ye M Benzaquen MJ Moore S Kamel-Reid MH Freedman H Yeger LZ Penn 2001 Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications Clin Cancer Res 7 158 167 11205904 1:CAS:528:DC%2BD3MXht1WhtrY%3D (Pubitemid 32110219)
86. J Damrot T Nübel B Epe WP Roos B Kaina G Fritz 2006 Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide Br J Pharmacol 149 988 997 17088865 10.1038/sj.bjp.0706953 1:CAS:528:DC%2BD28Xht12gsLjM (Pubitemid 44950802)
87. SJ Cho JS Kim JM Kim JY Lee HC Jung IS Song 2008 Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice Int J Cancer 123 951 957 18521906 10.1002/ijc.23593 1:CAS:528:DC%2BD1cXovFWmu7g%3D (Pubitemid 352032426)
88. T Narisawa Y Fukaura K Terada A Umezawa N Tanida K Yazawa C Ishikawa 1994 Prevention of 1, 2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice Carcinogenesis 15 2045 2048 7923600 10.1093/carcin/15.9.2045 1:CAS:528:DyaK2cXmsVGntr4%3D (Pubitemid 24303058)
89. Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ (2010) Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer online Mar 3
90. A Thibault D Samid AC Tompkins WD Figg MR Cooper RJ Hohl J Trepel B Liang N Patronas DJ Venzon E Reed CE Myers 1996 Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clin Cancer Res 2 483 491 9816194 1:CAS:528:DyaK28XitVymu7o%3D
91. WS Kim MM Kim HJ Choi SS Yoon MH Lee K Park CH Park WK Kang 2001 Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma Invest New Drugs 19 81 83 11291836 10.1023/A:1006481423298 1:CAS:528: DC%2BD3MXisFyqsL0%3D (Pubitemid 32209788)
92. JJ Knox LL Siu E Chen J Dimitroulakos S Kamel-Reid MJ Moore S Chin J Irish S LaFramboise AM Oza 2005 A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix Eur J Cancer 41 523 530 15737556 10.1016/j.ejca.2004.12.013 1:CAS:528:DC%2BD2MXhvVChtrg%3D (Pubitemid 40292732)
93. J Larner J Jane E Laws R Packer C Myers M Shaffrey 1998 A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme Am J Clin Oncol 21 579 583 9856659 10.1097/00000421-199812000-00010 1:STN:280:DyaK1M%2Fnt1Ckuw%3D%3D (Pubitemid 28558348)
94. S Kawata E Yamasaki T Nagase Y Inui N Ito Y Matsuda M Inada S Tamura S Noda Y Imai Y Matsuzawa 2001 Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial Br J Cancer 84 886 891 11286466 10.1054/bjoc.2000.1716 1:CAS:528:DC%2BD3MXktVaqu74%3D (Pubitemid 32385829)
95. C Lersch R Schmelz J Erdmann R Hollweck E Schulte-Frohlinde F Eckel M Nader V Schusdziarra 2004 Treatment of HCC with pravastatin, octreotide, or gemcitabine-a critical evaluation Hepatogastroenterology 51 1099 1103 15239254 1:CAS:528:DC%2BD2cXlslaltLY%3D (Pubitemid 38822478)
96. W Wang E Collie-Duguid J Cassidy 2002 Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines FEBS Lett 531 415 420 12435585 10.1016/S0014-5793(02)03575-5 1:CAS:528:DC%2BD38XosFCks7Y%3D (Pubitemid 35336061)
97. W Feleszko I Mlynarczuk EZ Balkowiec-Iskra A Czajka T Switaj T Stoklosa A Giermasz M Jakóbisiak 2000 Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice Clin Cancer Res 6 2044 2052 10815931 1:CAS:528:DC%2BD3cXktVWitro%3D (Pubitemid 30305104)
98. W Feleszko R Zagozdzon J Golab M Jakóbisiak 1998 Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice Eur J Cancer 34 406 411 9640231 10.1016/S0959-8049(97)10034-X 1:CAS:528:DyaK1cXivVSjurs%3D (Pubitemid 28183843)
99. MR Soma P Pagliarini G Butti R Paoletti P Paoletti R Fumagalli 1992 Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N, N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells Cancer Res 52 4348 4355 1643632 1:CAS:528:DyaK38XmtVCmtb0%3D
100. A Huether M Höpfner V Baradari D Schuppan H Scherübl 2005 EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer Biochem Pharmacol 70 1568 1578 16226226 10.1016/j.bcp.2005.09.007 1:CAS:528:DC%2BD2MXhtFKhsL%2FJ (Pubitemid 41540350)
101. DR Budman J Tai A Calabro 2007 Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro Breast Cancer Res Treat 104 93 101 17004104 10.1007/s10549-006-9395-5 1:CAS:528:DC%2BD2sXmvVygtbY%3D (Pubitemid 46976636)
102. C Cemeus TT Zhao GM Barrett IA Lorimer J Dimitroulakos 2008 Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status J Neurooncol 90 9 17 18566746 10.1007/s11060-008-9627-0 1:CAS:528:DC%2BD1cXht1ejtLbM
103. Dimitroulakos J, Lorimer IA, Goss G (2006) Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin Cancer Res 12(14 Pt 2):4426s-4431s (Pubitemid 44197193)
104. Shimoyama S. Statins and gastric cancer risk. Hepatogastroenterology (in press)
105. KM Dale CI Coleman NN Henyan J Kluger CM White 2006 Statins and cancer risk: a meta-analysis JAMA 295 74 80 16391219 10.1001/jama.295.1.74 1:CAS:528:DC%2BD28XhtlOgsQ%3D%3D (Pubitemid 43042692)